Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
In 2024, Myriad Genetics was awarded three patents related to foundational platform MRD technology and cell-free DNA preparation methods that each enable highly sensitive and specific tumor-informed, ...
Myriad Genetics, Inc.: Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and tumor genomic testing and precision medicine, announced that the United States Patent and ...
Business Insider1d
Myriad Genetics issued two new patents from USPTO
Myriad Genetics (MYGN) announced that the United States Patent ... MRD methods that are performed via an automation system configured to interface with laboratory equipment. U.S. patent No. 12,215,392 ...
Myriad Genetics secures patents for cancer MRD tests
SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine with annual revenues of $824 million, has announced the issuance of two ...
Gene Panel Market Size To Worth USD 13.2 Billion By 2030 With A 20.02 % CAGR By Exactitude Consultancy
The gene panel market is expected to grow at 20.02 % CAGR from 2023 to 2030. It is expected to reach above USD 13.2 billion by 2030 from USD 3.02 billion in 2023. List of the Top Key Players of the ...
Myriad Genetics (NASDAQ:MYGN) Given New $14.00 Price Target at Piper Sandler
Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its target price cut by analysts at Piper Sandler from $24.00 to $14.00 in a research note issued on Thursday,Benzinga reports. The brokerage ...
Yahoo Finance6d
Myriad Genetics, Inc. (MYGN)
Opening plenary session features latest fetal fraction amplification researchSALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and ...